Advertisement
News
Advertisement

First Hotspur Peripheral Angioplasty Case Completed

Tue, 01/18/2011 - 1:35am
Bio-Medicine.Org

MOUNTAIN VIEW, Calif., Jan. 18, 2011 /PRNewswire/ -- Hotspur Technologies, Inc. announced today that Dr. Greg Sampognaro, Interventional Cardiologist at P & S Surgical Hospital in Monroe, Louisiana, successfully completed the first use of the GPSCath™ Balloon Dilatation Catheter in an intervention to treat a blocked peripheral artery.  Successful use of the GPSCath Catheter in this type of procedure confirms the ability of this device to assist patients who suffer from peripheral arterial disease (PAD).

Hotspur's GPSCath Catheter, a two-in-one device that performs high-pressure angioplasty with a semi-compliant balloon, while also offering the ability to inject physician-specified fluids through Hotspur's proprietary VisioValve™ injection system, has already been commercially used in dialysis access procedures.  However, this expanded utilization of the device shows Hotspur's ability to target additional markets with devices that are already commercially available, while working within the devices' indications for use.

During the procedure, Dr. Sampognaro utilized a 6mm GPSCath balloon to cross and successfully dilate two high-grade stenoses in the patient's distal superficial femoral artery.  After this balloon inflation, the VisioValve system on the balloon was opened, and an angiogram was performed to assess the angioplasty results without requiring removal of the balloon or adjustment of the guidewire.  After subsequently placing a stent to treat the remaining blockage, Dr. Sampognaro reinserted the GPSCath balloon to further expand the stent before again utilizing the balloon's VisioValve system to inject contrast to perform the case's final angiogram.

"The ability to inject contrast through the catheter without having to remove the balloon from the artery or adjust the wire saved a lot of time, produced excellent contrast injection quality, and simplified the procedure overall," said Dr. Sampognaro. &

'/>"/>

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading